Expression and clinical significance of paired related homoeobox-1 and cancer susceptibility candidate-2 in primary hepatic carcinoma

Abstract

Abstract: Objective: To investigate the expression of paired related homoeobox-1 (PRRX1) and cancer susceptibility candidate-2 (CASC2) in primary hepatic carcinoma, and analyze their relationship with clinicopathological parameters and prognosis.
Methods: Paraffin specimens were collected from 72 patients with primary hepatic carcinoma from January 2014 to January 2017. The expressions of PRRX1 and CASC2 were detected by real-time fluorescence quantitative polymerization chain reaction (qRT-PCR), and the relationship between the expressions of PRRX1 and CASC2 and the clinicopathological parameters of primary hepatic carcinoma was analyzed. The relationship between the expression of PRRX1 and CASC2 and the prognosis of primary hepatic carcinoma patients was analyzed with death of primary hepatic carcinoma patients as the endpoint event during follow-up.
Results: The expression of PRRX1 and CASC2 in primary hepatic carcinoma tissues was lower than that in para-carcinoma tissues (P<0.05). The expression of PRRX1 was associated with vascular invasion, intrahepatic metastasis, distal metastasis and TNM stage (P<0.05). The expression of CASC2 was associated with the degree of differentiation and TNM stage (P<0.05). The results of Kaplan-Meier survival curve analysis showed that the survival rate of primary hepatic carcinoma in the low-expression group of PRRX1 and CASC2 was lower than that in the high-expression group of PRRX1 and CASC2 (P<0.05). Multivariate Cox regression analysis showed that distal metastasis, low expression of PRRX1 and CASC2 were independently correlated with poor prognosis of primary hepatic carcinoma patients (P<0.01).
Conclusions: PRRX1 and CASC2 were under expressed in primary hepatic carcinoma. Low expression of PRRX1 and CASC2 in primary hepatic carcinoma may be related to the pathogenesis and malignant progression of primary hepatic carcinoma, which can be used as an auxiliary indicator for the prognosis assessment of primary hepatic carcinoma.

Key words: Paired related homoeobox-1 proteins, Cancer susceptibility candidate-2, Primary hepatic carcinoma

Li Wenchao, Zhang Dong, Zhang Dongxia. Expression and clinical significance of paired related homoeobox-1 and cancer susceptibility candidate-2 in primary hepatic carcinoma[J]. Electronic Journal of Liver Tumor, 2021, 8(4): 21-25.

References

[1] GLOBAL BURDEN OF DISEASE LIVER CANCER COLLABORATION, AKINYEMIJU T, ABERA S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.
[2] ALLEMANI C, MATSUDA T, DI C V, et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37, 513, 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
[3] FAN M, SHEN J, LIU H, et al.Downregulation of PRRX1 via the p53-dependent signaling pathway predicts poor prognosis in hepatocellular carcinoma[J]. Oncol Rep, 2017, 38(2): 1083-1090.
[4] JIN X, CAI L, WANG C, et al.CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3[J]. Cell Death Dis, 2018, 9(3): 318.
[5] YU X, ZHENG H, TSE G, et al.CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma[J]. Cell Prolif, 2018, 51(6): e12506.
[6] EDGE S B, COMPTON C C.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474.
[7] PIRISI M, LEUTNER M, PINATO D J, et al.Reliability and reproducibility of the edmondso grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens[J]. Arch Pathol Lab Med, 2010, 134(12): 1818-1822.
[8] GLANTZOUNIS G K, KYROCHRISTOS I D, ZIOGAS D E, et al.Novel translational therapeutic strategy by sequencing primary liver cancer genomes[J]. Future Oncol, 2017, 13(12): 1049-1052.
[9] SAITOH M.Involvement of partial EMT in cancer progression[J]. J Biochem, 2018, 164(4): 257-264.
[10] MARCHAND B, PITARRESI J R, REICHERT M, et al.PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells[J]. Oncogene, 2019, 38(22): 4325-4339.
[11] 李宁宁, 郭振英. PRRX1在EMT及维持肿瘤干性中的研究进展[J]. 临床与实验病理学杂志, 2018, 34(4): 433-435.
[12] MARCHAND B, PITARRESI J R, REICHERT M, et al.PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells[J]. Oncogene, 2019, 38(22): 4325-4339.
[13] GUO J, FU Z, WEI J, et al.PRRX1 promotes epithelial-mesenchymal transition through the Wnt/β-catenin pathway in gastric cancer[J]. Med Oncol, 2015, 32(1): 393.
[14] 范丹, 宋文静, 张艳辉, 等. PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J]. 天津医科大学学报, 2018, 24(1): 1-6.
[15] 尹东亮, 卢沛林, 尹润龙, 等. 过表达PRRX1通过p53介导的线粒体凋亡途径诱导肝癌SMMC7721细胞凋亡[J]. 中国肿瘤生物治疗杂志, 2019, 26(6): 662-668.
[16] HIRATA H, SUGIMACHI K, TAKAHASHI Y, et al.Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2015, 22(Suppl 3): S1402-S1409.
[17] RANSOHOFF J D, WEI Y, KHAVARI P A.The functions and unique features of long intergenic non-coding RNA[J]. Nat Rev Mol Cell Biol, 2018, 19(3): 143-157.
[18] SANCHEZ CALLE A, KAWAMURA Y, YAMAMOTO Y, et al.Emerging roles of long non-coding RNA in cancer[J]. Cancer Sci, 2018, 109(7): 2093-2100.
[19] WANG Y F, LIU Z K, YAO B W, et al.Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis[J]. Mol Cancer, 2017, 16(1): 123.
[20] ZHAO L, ZHANG Y J, ZHANG Y B.Long noncoding RNA CASC2 regulates hepatocellular carcinoma cell oncogenesis through miR-362-5p/Nf-κB axis[J]. J Cell Physiol, 2018, 233(10): 6661-6670.
[21] 罗剑, 王媛媛, 李爱玲, 等. 癌易感性候选基因2表达与恶性肿瘤预后相关性的系统评价[J]. 实用医学杂志, 2019, 35(1): 66-70.
[22] 辛海光, 周惠娟, 谢青. 原发性肝细胞癌的分子靶向治疗进展[J]. 肝脏, 2019, 24(7): 736-738.